Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Total Non-Current Liabilities for 5 consecutive years, with $93.5 million as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 18.7% to $93.5 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $93.5 million through Dec 2024, up 18.7% year-over-year, with the annual reading at $93.5 million for FY2024, 18.7% up from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $93.5 million at Relay Therapeutics, up from $90.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $126.0 million in Q3 2022, with the low at $36.5 million in Q4 2020.
  • Average Total Non-Current Liabilities over 5 years is $83.8 million, with a median of $84.3 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 151.74% in 2022, then plummeted 32.77% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $36.5 million in 2020, then surged by 65.25% to $60.4 million in 2021, then surged by 94.07% to $117.2 million in 2022, then tumbled by 32.77% to $78.8 million in 2023, then rose by 18.7% to $93.5 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $93.5 million, $90.8 million, and $84.3 million for Q4 2024, Q2 2024, and Q1 2024 respectively.